Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

por Gettinger, Scott N., Huber, Rudolf M., Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J., Paz-Ares Rodríguez, Luis G., West, Howard L., Reckamp, Karen L., Weiss, Glen J., Smit, Egbert F., Hochmair, Maximilian J., Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S., Groen, Harry J.M., Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, Camidge, D. Ross
Publicado 2022